Cardiol Therapeutics Inc Class A
$ 1.38
0.00%
10 Apr - close price
- Market Cap 154,119,000 USD
- Current Price $ 1.38
- High / Low $ 1.44 / 1.37
- Stock P/E N/A
- Book Value 0.08
- EPS -0.28
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -1.59 %
- 52 Week High 1.59
- 52 Week Low 0.88
About
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
Analyst Target Price
$7.44
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-01 | 2025-12-31 | 2025-11-18 | 2025-08-19 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-12 | 2024-04-01 | 2024-03-28 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.0516 | -0.07 | -0.0857 | -0.0722 | -0.1 | -0.09 | -0.18 | -0.1 | -0.12 | -0.09 | -0.09 | -0.12 |
| Estimated EPS | -0.0826 | -0.11 | -0.0775 | -0.0997 | -0.08 | -0.1167 | -0.08 | -0.13 | -0.12 | -0.09 | -0.12 | -0.12 |
| Surprise | 0.031 | 0.04 | -0.0082 | 0.0275 | -0.02 | 0.0267 | -0.1 | 0.03 | 0 | 0 | 0.03 | 0 |
| Surprise Percentage | 37.5303% | 36.3636% | -10.5806% | 27.5827% | -25% | 22.8792% | -125% | 23.0769% | 0% | 0% | 25% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRDL
2026-04-11 17:40:03
Cardiol Therapeutics has announced that its annual general meeting of shareholders will be held on June 24, 2026, with a record date of May 7, 2026, for voting eligibility. The company, a foreign private issuer reporting under Form 40-F, has also detailed its notice-and-access delivery method for proxy materials. Analysts currently rate CRDL stock as a Hold with a C$2.00 price target, and TipRanks’ AI Analyst, Spark, also provides a "Neutral" score, citing weak financial performance offset by a low-debt balance sheet and positive technicals.
2026-04-10 17:09:43
Cardiol Therapeutics has announced that its Annual General Meeting of Shareholders will take place on June 24, 2026, with May 7, 2026, as the record date for voting eligibility for Class A shareholders. The company confirmed its foreign private issuer status with the U.S. SEC and outlined standard governance processes for investor participation in the meeting. Currently, analysts rate CRDL stock as a Hold, with TipRanks' AI Analyst, Spark, also rating it Neutral due to weak financial performance despite an improving uptrend in technicals.
2026-04-10 17:09:43
Cardiol Therapeutics Inc. (CRDL) has scheduled its Annual General Meeting (AGM) for June 24, 2026, with a record date of May 7, 2026, for both notice and voting rights as well as determining beneficial ownership. The meeting will involve holders of Class A Common shares and will utilize notice-and-access procedures for proxy materials. Odyssey Trust Company will act as the agent for Cardiol in this process.
2026-04-01 09:09:35
Cardiol Therapeutics Inc. has filed its Annual Report on Form 40-F, which includes its audited financial statements for the fiscal year ended December 31, 2025. The report indicates 100,257,009 shares outstanding and confirms that management assessed internal controls as effective. The company reported audit fees of $403,570 for 2025 and prepares its financials under IFRS in Canadian dollars.
2026-03-26 19:09:44
This article displays tax information for Cardiol Therapeutics Inc. Class A (HAM:CT9). It includes a table with period, value, change, and change percentage data, set against the backdrop of TradingView's financial data and tools. The page seems to be a financial data presentation rather than an analytical article.
2026-02-25 14:51:41
Cardiol Therapeutics will present updates on its cardiovascular pipeline at the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The presentation will highlight progress in its Phase III MAVERIC trial and Phase II ARCHER study, as well as the development of CRD-38. Despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance, the company aims to increase investor visibility for its late-stage programs.
